TMX Newsfile
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
📈
AI Sentiment
Highly Positive
8/10
- Home
- PHIO
as of 03-09-2026 3:42pm EST
$1.21
+$0.02
+1.67%
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
| Founded: | 2011 | Country: | United States |
| Employees: | 5 | City: | KING OF PRUSSIA |
| Market Cap: | 12.5M | IPO Year: | 2011 |
| Target Price: | $10.67 | AVG Volume (30 days): | 7.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | -74.62 |
| 52 Week Low/High: | $0.81 - $4.19 | Next Earning Date: | 06-17-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.38 | Index: | N/A |
| Free Cash Flow: | -7991000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Phio Pharmaceuticals Corp. (PHIO)
Bitterman Robert J
Buy
Chairman, Pres. & CEO
PHIO Dec 31, 2025
Avg Cost/Share
$1.03
Shares
5,000
Total Value
$5,150.00
Owned After
291,421
SEC Form 4
Bitterman Robert J
Buy
Chairman, Pres. & CEO
PHIO Dec 23, 2025
Avg Cost/Share
$1.02
Shares
5,000
Total Value
$5,100.00
Owned After
291,421
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bitterman Robert J | PHIO | Chairman, Pres. & CEO | Dec 31, 2025 | Buy | $1.03 | 5,000 | $5,150.00 | 291,421 | |
| Bitterman Robert J | PHIO | Chairman, Pres. & CEO | Dec 23, 2025 | Buy | $1.02 | 5,000 | $5,100.00 | 291,421 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 5, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 5, 2026 · 100% conf.
AI Prediction SELL
1D
-3.12%
$1.13
Act: +1.71%
5D
-17.92%
$0.96
20D
-9.29%
$1.06
Price: $1.17 Prob +5D: 0% AUC: 1.000
0001437749-26-007071
phio20251215_8k.htm
false 0001533040
0001533040
2026-03-05 2026-03-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 5, 2026
PHIO PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-36304
45-3215903
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
411 Swedeland Road, Suite 23-1080
King of Prussia, PA
19406
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (610) 947-0251
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s):
Name of each exchange on which registered:
Common Stock, par value $0.0001 per share
PHIO
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 5, 2026, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Number
Description
99.1
Press release issued by the Company on March 5, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PHIO PHARMACEUTICALS CORP.
Date: March 5, 2026
By:
/s/ Robert Bitterman
Name:
Title:
Robert Bitterman
President & Chief Executive Officer
3
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 13, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 13, 2025 · 100% conf.
AI Prediction SELL
1D
-1.92%
$1.48
Act: -13.91%
5D
-17.55%
$1.24
Act: -21.19%
20D
-7.45%
$1.40
Act: -25.83%
Price: $1.51 Prob +5D: 0% AUC: 1.000
0001437749-25-034848
phio20251001_8k.htm
false 0001533040
0001533040
2025-11-13 2025-11-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2025
PHIO PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-36304
45-3215903
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
411 Swedeland Road, Suite 23-1080
King of Prussia, PA
19406
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (610) 947-0251
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s):
Name of each exchange on which registered:
Common Stock, par value $0.0001 per share
PHIO
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 13, 2025, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release issued by the Company on November 13, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PHIO PHARMACEUTICALS CORP.
Date: November 13, 2025
By:
/s/ Robert J. Bitterman
Robert J. Bitterman
President & Chief Executive Officer
3
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 14, 2025
0001683168-25-006171
8-K
false 0001533040
0001533040
2025-08-14 2025-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 14, 2025
PHIO
PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-36304
45-3215903
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
411 Swedeland Road, Suite 23-1080
King of Prussia, PA 19406
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s):
Name of each exchange on which registered:
Common Stock, par value $0.0001 per share
PHIO
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2025, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release issued by the Company on August 14, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PHIO PHARMACEUTICALS CORP.
Date: August 14, 2025 By: /s/ Robert J. Bitterman
Robert J. Bitterman
President & Chief Executive Officer
3
Latest Phio Pharmaceuticals Corp. News
PHIO Breaking Stock News: Dive into PHIO Ticker-Specific Updates for Smart Investing
TMX Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
📈
AI Sentiment
Highly Positive
8/10
Compare PHIO vs Leading Stocks
See how PHIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PHIO Phio Pharmaceuticals Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.